Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

Background: Etoposide phosphate (VP-16) is a topoisomerase 2 (TOP2) inhibitor that demonstrated activity in patients with metastatic castration-resistant prostate cancer (mCRPC). We investigated the sensitivity of prostate cancer (PCa) cells (LNCaP, 22Rv1, PC3, DU145, PDB and MDB) to VP-16 and the p...

Full description

Bibliographic Details
Main Authors: Carlo Cattrini, Matteo Capaia, Francesco Boccardo, Paola Barboro
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Prostate cancer, mcrpc mCRPC
VP-16 V
Etoposide
TOP2A
NEPC
AVPC
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220300563

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220300563

Similar Items